Somewhat Positive News Coverage Somewhat Unlikely to Impact OncoGenex Pharmaceuticals (ACHV) Share Price

News articles about OncoGenex Pharmaceuticals (NASDAQ:ACHV) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OncoGenex Pharmaceuticals earned a news impact score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.8137026398866 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of OncoGenex Pharmaceuticals (NASDAQ:ACHV) opened at $1.38 on Monday. OncoGenex Pharmaceuticals has a 12-month low of $1.25 and a 12-month high of $10.23.

OncoGenex Pharmaceuticals (NASDAQ:ACHV) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter.

Separately, ValuEngine downgraded shares of OncoGenex Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://transcriptdaily.com/2017/12/11/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-oncogenex-pharmaceuticals-achv-share-price.html.

OncoGenex Pharmaceuticals Company Profile

Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.

Insider Buying and Selling by Quarter for OncoGenex Pharmaceuticals (NASDAQ:ACHV)

Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply